Lunch Roundtable Discussions
12:30 PM - 1:30 PM
A new opportunity to network with peers from the healthcare community, the roundtable discussions will bring together Summit attendees from different stakeholder organizations, as well as the biotechnology industry, for robust discussions led by roundtable hosts.
Best Practices in Creating Patient Centric Clinical Trials
Hosted by: Shire
A discussion to explore successes, challenges and best practices in advancing rare disease R&D by integrating patients’ points of view during the discovery and development lifecycle including:
- Patient, caregiver and advocacy group input into clinical trial design and processes
- Patient & patient advocacy group engagement with the FDA
- Accelerating clinical trial recruitment
- Patient registry creation and management to support patient reported outcome & natural history data collection
Melanie Ivarsson, Director of Clinical Programs for Global Research and Development
Lilly Advocacy Dialogues: Listening Tour – What are Your Priorities?
Hosted by: Eli Lilly and Company
During this interactive conversation, Lilly Advocacy leadership wants to hear from YOU! What are your organization’s key policy priorities both in the short term and over the long haul? What are your concerns, and ideas as to how to address them.
Michele M. Oshman, Director, Federal Advocacy and Alliance Development
Tom Wallace, Senior Director, Global Advocacy and Professional Relations
The Future of Value 101: Value Based Contracting
Hosted by: Bristol-Myers Squibb
Patients will be better served in a health care system based on value, but what does that mean? Join Bristol-Myers Squibb and their US Health Policy Lead, Stefanie Wiegand, for a 101 introductory discussion on value and how we can move towards value based contracting for healthcare services and products.
Stefanie Wiegand, US Health Policy Lead
Personalized Medicine: “Is This Therapy Going to Work for Me?”
Hosted by: BIO
A customizable healthcare model where medical decisions, practices, and/or products are tailored to the individual patient based on an individual’s genetic profile is no longer a fantasy. This discussion will focus on issues surrounding genetic testing such as access, privacy, targeted therapies, and whether patients should get tested.
Phi D. Vu, JD, Director, Diagnostics and Personalized Medicine Policy